Literature DB >> 19790142

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.

Francesco D'Amico1, Myron Schwartz, Alessandro Vitale, Parissa Tabrizian, Sasan Roayaie, Swan Thung, Maria Guido, Juan del Rio Martin, Thomas Schiano, Umberto Cillo.   

Abstract

The up-to-seven (Up-to-7) criteria [with 7 being the sum of the size and number of tumors for any given hepatocellular carcinoma (HCC)] have been recently proposed to identify potential candidates for liver transplantation (LT) among patients exceeding the Milan criteria. The aim of this study was to compare the ability of the available pathologic staging systems (the Milan, University of California San Francisco, and Up-to-7 criteria) to predict recurrence. A study population of 479 HCC transplanted patients was identified from prospectively collected databases at Mount Sinai Medical Center (New York, NY) and the University of Padua (Padua, Italy). The best pathologic staging system was identified with log rank, proportion separation index (PSEP), and Cox analyses. Pathologic tumor characteristics (tumor number, tumor size, sum of diameters, macroscopic and microscopic vascular invasion, and grading) were then tested by univariate and multivariate Cox analyses in the prognostic subgroups within and beyond the calculated criteria. The Up-to-7 criteria performed as the best pathologic staging system, the calculated 1-, 3-, and 5-year recurrence probabilities being 4%, 8%, and 14% within the criteria (n = 355) and 22%, 45%, 51% beyond the criteria (n = 124; P < 0.0001) and the calculated PSEP being 0.27 (95% confidence interval = 0.23-0.31). In multivariate analysis, only biological variables (vascular invasion and tumor grade) significantly predicted recurrence beyond the Up-to-7 criteria. A 3-stage pathologic staging system with a potential to be applied in the preoperative setting was thus created: within the Up-to-7 criteria (recurrence rate = 8%), beyond the Up-to-7 criteria without macrovascular invasion and poorly differentiated grade (recurrence rate = 24%), and beyond the Up-to-7 criteria with macrovascular invasion and/or poorly differentiated grade (recurrence rate = 45%). In conclusion, HCC patients within the pathologic Up-to-7 criteria were associated with a low risk of recurrence after LT. Beyond these criteria, however, a significant proportion of patients with a good HCC biological profile had an acceptable risk of recurrence. Copyright 2009 AASLD

Entities:  

Mesh:

Year:  2009        PMID: 19790142     DOI: 10.1002/lt.21842

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  29 in total

1.  Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience.

Authors:  Donal B O'Connor; John P Burke; John Hegarty; Aiden P McCormick; Niamh Nolan; Emir Hoti; Donal Maguire; Justin Geoghegan; Oscar Traynor
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

3.  Liver transplantation for hepatocellular carcinoma: alpha-fetoprotein should be included in selection criteria.

Authors:  Hans-Christian Pommergaard
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-11

Review 4.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 5.  Liver transplantation for advanced hepatocellular carcinoma: how far can we go?

Authors:  Kyung-Suk Suh; Hae Won Lee
Journal:  Hepat Oncol       Date:  2015-01-12

6.  Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Stefano Merolla; Simona Francioso; Costantino Del Giudice; Mario Angelico; Giuseppe Tisone; Giovanni Simonetti
Journal:  World J Hepatol       Date:  2015-06-28

Review 7.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

Review 8.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

9.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25

10.  Liver Transplantation for HCC: A Review.

Authors:  Rahul Kakodkar; A S Soin
Journal:  Indian J Surg       Date:  2011-12-27       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.